Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)

The American Journal of Cardiology
Terje R PedersenMichael Szarek

Abstract

Previous studies have demonstrated that benefits of intensive statin therapy compared to standard statin therapy begin shortly after an acute event and are continued up to 2 years of follow-up. However, whether efficacy and safety of intensive statin therapy in patients with a recent cardiac event are maintained in longer-term follow-up has not been evaluated. We conducted a post hoc analysis of a subgroup of 999 patients who had a first acute myocardial infarction (MI) <2 months before randomization in a prospective, open-label, blinded end-point evaluation trial of 8,888 patients with a history of MI that compared intensive statin therapy (atorvastatin 80 mg) to standard statin therapy (simvastatin 20 to 40 mg) over approximately 5 years of follow-up. We analyzed the same composite end point used in the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) trial (death, MI, hospitalization for unstable angina, revascularization, and stroke). Rates of the composite end point were 44.7% (n = 226) in the simvastatin group and 37.9% (n = 187) in the atorvastatin group (hazard ratio 0.82, 95% confidence interval 0.67 to 0.99, p = 0.04). Although statistical power was smaller than that of the PROVE IT trial, the r...Continue Reading

References

Apr 13, 2001·JAMA : the Journal of the American Medical Association·G G SchwartzUNKNOWN Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Aug 13, 2004·The New England Journal of Medicine·Pim van der HarstDirk J van Veldhuisen
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Sep 18, 2004·The American Journal of Cardiology·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
May 4, 2006·JAMA : the Journal of the American Medical Association·Matthias BrielAlain J Nordmann
Mar 27, 2009·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Ingar HolmeUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group
Oct 3, 2009·Journal of the American College of Cardiology·Ryan P MorrisseySanjay Kaul

❮ Previous
Next ❯

Citations

Nov 2, 2011·Internal and Emergency Medicine·Diego Vanuzzo
Jul 12, 2011·Current Opinion in Lipidology·Alberico L CatapanoAngela Pirillo
Apr 8, 2011·Clinical Interventions in Aging·Sydney B LongErin D Michos
Aug 9, 2013·Antioxidants & Redox Signaling·Nerea Hermida, Jean-Luc Balligand
Mar 8, 2016·Trends in Cardiovascular Medicine·Nikolaos PapageorgiouDimitris Tousoulis
Nov 8, 2011·British Journal of Clinical Pharmacology·Jean Davignon
Nov 2, 2015·Atherosclerosis·Monica VerdoiaUNKNOWN Novara Atherosclerosis Study Group (NAS)
Dec 24, 2010·Journal of cardiology·Michinari NakamuraUNKNOWN Shinken Database Study Group
Aug 1, 2007·Journal of Vascular Surgery·Kosmas I ParaskevasDimitri P Mikhailidis
Feb 28, 2017·Journal of Atherosclerosis and Thrombosis·Yu KataokaStephen J Nicholls
Mar 5, 2011·The Journal of Medical Investigation : JMI·Miyako KishimotoMitsuhiko Noda
Jan 17, 2017·Annales d'endocrinologie·UNKNOWN French Society of Endocrinology (SFE)B Vergès
Aug 12, 2014·Journal of Pharmacy Practice·Pavel GoriackoRoda Plakogiannis
Mar 12, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Ali OlyaeiJose Rueda
Dec 21, 2013·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Mary Chester WaskoMahboob U Rahman
Oct 15, 2019·Journal of the American Heart Association·Adam D GepnerCynthia M Carlsson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

JAMA : the Journal of the American Medical Association
Daniel I ChasmanPaul M Ridker
The American Journal of Cardiology
James K Liao
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
Peng LiuYong Huo
Journal of the American College of Nutrition
Maria Luz Fernandez, Densie Webb
© 2021 Meta ULC. All rights reserved